Georgina Long, BSc, PhD, MBBS, FRACP, FAHMS, The University of Sydney, Sydney, Australia, comments on data from the Phase II LEAP-004 study (NCT03776136), which assessed lenvatinib and pembrolizumab in patients with melanoma who progressed on PD-1/L1 inhibitors such as ipilimumab, unlike in the NeoPeLe trial (NCT04207086), which only recruited patients with resectable melanoma. Lenvatinib and pembrolizumab represent a promising therapy for these patients of high unmet need, where a durable response was recorded in patients receiving the investigational treatment. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.